Pharma BD Deal Intelligence

Novo Nordisk A/S / Ablexis, LLC

2026 · Licensing/Option · Complete

Ablexis granted Novo Nordisk a non-exclusive license to its proprietary AlivaMab Mouse human antibody drug discovery platforms, giving Novo the right to possess and use AlivaMab Mouse strains to generate human VH/VL antibodies and to discover, develop and commercialise biologics comprising AlivaMab antibodies. The license adds in-house capacity at the earliest stage of antibody discovery rather than conveying a specific asset. Neither party disclosed financial terms.

Key facts

• Announced Oct 14, 2026
• Deal type Licensing/Option

Related deals

• Novo Nordisk A/S / Emisphere Technologies (2020)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2019)
• Novo Nordisk A/S / Vivtex Inc. (2026)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2021)
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (2022)
• Novo Nordisk A/S / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (2026)

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novo Nordisk A/S deals